Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Indinavir Sulfate

FDA-approved product (capsule, oral), marketed as Crixivan.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Indinavir Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • HIV infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Protease inhibitors
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AE02

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis, MRSA and E. coli. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA46.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis55.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Indinavir Sulfate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Indinavir Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Interaction With HIV Antiretroviral Agents

    NCT02556268 · start 2016-02-23

    Registered record
    Registry ID
    NCT02556268
    Conditions
    HIV-DDI
    Interventions
    Riociguat (Adempas, BAY 63-2521); ATRIPLA; COMPLERA; STRIBILD; TRIUMEQ; Antiretroviral protease inhibitor
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-02-23
    Completion
    2016-12-07
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV-DDI
    InterventionRiociguat (Adempas, BAY 63-2521); ATRIPLA; COMPLERA; STRIBILD +2 more
    PhasePhase 1
    Registry statusCompleted

  • Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy

    NCT02302547 · start 2014-12

    Registered record
    Registry ID
    NCT02302547
    Conditions
    HIV
    Interventions
    triple therapy; dual therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-12
    Completion
    2018-09-21
    Enrolment
    224

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV
    Interventiontriple therapy; dual therapy
    PhasePhase 3
    Registry statusCompleted

  • The Study of HIV Protease Inhibitors and Their Effects on Glucose Metabolism

    NCT00259727 · start 2006-01

    Registered record
    Registry ID
    NCT00259727
    Conditions
    Diabetes; HIV Infections; Insulin Resistance
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2006-01
    Completion
    2008-09
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes; HIV Infections; Insulin Resistance
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Efficacy and Safety of SQV in Patients Who Have Chronic IDV Nephrotoxicity

    NCT00477048 · start 2004-05

    Registered record
    Registry ID
    NCT00477048
    Conditions
    IDV Associated Nephrotoxicity
    Interventions
    Saquinavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-05
    Completion
    2008-05
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIDV Associated Nephrotoxicity
    InterventionSaquinavir
    PhasePhase 2
    Registry statusCompleted

  • Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy

    NCT00042289 · start 2003-06-09

    Registered record
    Registry ID
    NCT00042289
    Conditions
    HIV Infections
    Interventions
    atazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3; elvitegravir/cobicistat; dolutegravir; tenofovir alafenamide fumarate (TAF); TAF w/cobicistat; TAF w/cobicistat or ritonavir; efavirenz; darunavir/cobicistat; lopinavir/ritonavir dosage #1; atazanavir/ritonavir/tenofovir dosage #1; rifampicin; ethambutol; isoniazid; pyrazinamide; kanamycin; amikacin; capreomycin; moxifloxacin; levoflaxacin; ofloxacin; ethionamide/prothionamide; terizidone/cycloserine; para-aminosalicylic acid (PAS); high dose INH; bedaquiline; clofazamine; delamanid; linezolid; pretomanid; ethinyl estradiol; etonogestrel implant; nevirapine; amprenavir; abacavir; lopinavir/ritonavir dosage #2; indinavir/ritonavir dosage #1; fosamprenavir/ritonavir; lopinavir/ritonavir dosage #3; atazanavir/ritonavir dosage #1; didanosine delayed release (Videx® EC); emtricitabine; tenofovir; nelfinavir dosage #1; tipranavir/ritonavir; lopinavir/ritonavir dosage #4; ralteg
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2003-06-09
    Completion
    2020-09-30
    Enrolment
    1,578

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    Interventionatazanavir/cobicistat; darunavir/ritonavir dosage #1; darunavir/ritonavir dosage #2; darunavir/ritonavir dosage #3 +45 more
    PhaseNot recorded
    Registry statusCompleted

  • Randomised Trial of Structured Treatment Interruption of HAART in HIV-Infected Adults in Abidjan (ANRS 1269 TRIVACAN)

    NCT00158405 · start 2002-12

    Registered record
    Registry ID
    NCT00158405
    Conditions
    HIV Infections
    Interventions
    Structured Treatment Interruption; Zidovudine (ZDV); Lamivudine (3TC); Efavirenz (EFV); Ritonavir (NRV); Indinavir (IDV)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-12
    Completion
    2006-12
    Enrolment
    840

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionStructured Treatment Interruption; Zidovudine (ZDV); Lamivudine (3TC); Efavirenz (EFV) +2 more
    PhasePhase 3
    Registry statusCompleted

  • Influence of the MDR1 Genotype on Blood Levels of Indinavir and Saquinavir in Healthy Volunteers

    NCT00050180 · start 2002-11-22

    Registered record
    Registry ID
    NCT00050180
    Conditions
    Healthy; HIV Infections
    Interventions
    Midazolam; Indinavir; Saquinavir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-11-22
    Completion
    2007-08-24
    Enrolment
    81

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy; HIV Infections
    InterventionMidazolam; Indinavir; Saquinavir
    PhasePhase 4
    Registry statusCompleted

  • Depo-Medroxyprogesterone Acetate (DMPA, Depo-Provera) Use With Certain Anti-HIV Drugs in HIV-Infected Women

    NCT00016601 · start 2001-06

    Registered record
    Registry ID
    NCT00016601
    Conditions
    HIV Infections
    Interventions
    Indinavir sulfate; Ritonavir; Nelfinavir mesylate; Efavirenz; Nevirapine; Medroxyprogesterone acetate
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2001-06
    Completion
    2004-05
    Enrolment
    76

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIndinavir sulfate; Ritonavir; Nelfinavir mesylate; Efavirenz +2 more
    PhaseNot applicable
    Registry statusCompleted

  • Drug Interactions of Amprenavir and Efavirenz, in Combination With a Second Protease Inhibitor, in HIV-Negative Volunteers

    NCT00005762 · start 2001-03

    Registered record
    Registry ID
    NCT00005762
    Conditions
    HIV Infections
    Interventions
    Indinavir sulfate; Ritonavir; Amprenavir; Nelfinavir mesylate; Efavirenz; Saquinavir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2001-03
    Completion
    2004-05
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIndinavir sulfate; Ritonavir; Amprenavir; Nelfinavir mesylate +2 more
    PhaseNot applicable
    Registry statusCompleted

  • The Effect of Milk Thistle on the Pharmacokinetics of Indinavir

    NCT00011635 · start 2001-02

    Registered record
    Registry ID
    NCT00011635
    Conditions
    HIV Infection; Healthy
    Interventions
    Silymarin (milk thistle)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2001-02
    Completion
    2001-06
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection; Healthy
    InterventionSilymarin (milk thistle)
    PhasePhase 1
    Registry statusCompleted

  • A Study of Indinavir Plus Ritonavir Plus Two NRTIs vs. Nelfinavir Plus Two NRTIs in HIV Positive Patients (0639-112)(COMPLETED)

    NCT00541463 · start 2001-01

    Registered record
    Registry ID
    NCT00541463
    Conditions
    HIV Infections
    Interventions
    MK0639, indinavir sulfate / Duration of Treatment: 48 Weeks; Comparator: nelfinavir mesylate / Duration of Treatment: 48 Weeks
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2001-01
    Completion
    2003-05
    Enrolment
    330

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionMK0639, indinavir sulfate / Duration of Treatment: 48 Weeks; Comparator: nelfinavir mesylate / Duration of Treatment: 48 Weeks
    PhasePhase 2
    Registry statusCompleted

  • Effects on the Immune System of Anti-HIV Drugs in Patients Recently Infected With HIV

    NCT00001119 · start 1999-10

    Registered record
    Registry ID
    NCT00001119
    Conditions
    HIV Infections
    Interventions
    Tetanus Toxoid Vaccine; Indinavir sulfate; Lamivudine/Zidovudine; Ritonavir; Abacavir sulfate; Amprenavir; Efavirenz; Hepatitis B Vaccine (Recombinant); Lamivudine; Zidovudine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    1999-10
    Completion
    Not recorded
    Enrolment
    288

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionTetanus Toxoid Vaccine; Indinavir sulfate; Lamivudine/Zidovudine; Ritonavir +6 more
    PhaseNot applicable
    Registry statusCompleted

  • A Study to Compare the Safety and Effectiveness of Two Dosing Schedules of Lamivudine in Combination With Two Other Anti-HIV Drugs

    NCT00002442 · start 1999-06

    Registered record
    Registry ID
    NCT00002442
    Conditions
    HIV Infections
    Interventions
    Indinavir sulfate; Nelfinavir mesylate; Lamivudine; Stavudine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1999-06
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infections
    InterventionIndinavir sulfate; Nelfinavir mesylate; Lamivudine; Stavudine
    PhasePhase 2
    Registry statusCompleted

  • Paclitaxel in Treating Patients With AIDS-Related Kaposi's Sarcoma

    NCT00003008 · start 1997-12-15

    Registered record
    Registry ID
    NCT00003008
    Conditions
    Sarcoma
    Interventions
    indinavir sulfate; nelfinavir mesylate; paclitaxel; ritonavir; saquinavir mesylate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1997-12-15
    Completion
    Not recorded
    Enrolment
    33

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSarcoma
    Interventionindinavir sulfate; nelfinavir mesylate; paclitaxel; ritonavir +1 more
    PhasePhase 2
    Registry statusCompleted

  • Use of Combined Antiretroviral Therapy to Determine Sites of Persistent HIV Infection

    NCT00001644 · start 1997-03-03

    Registered record
    Registry ID
    NCT00001644
    Conditions
    HIV Infection
    Interventions
    Indinavir; Zidovudine; Lamivudine; Nevirapine; Blood testing; Lymph node biospy; Leukapheresis
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    1997-03-03
    Completion
    2010-02-17
    Enrolment
    42

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV Infection
    InterventionIndinavir; Zidovudine; Lamivudine; Nevirapine +3 more
    PhasePhase 1
    Registry statusCompleted